Nelson Advisors: The Lower Mid Market Is Where European HealthTech, MedTech and Health AI Value Gets Realised
The most consequential shift in European healthtech over the past three years has not happened at the top of the market. It has happened in the middle. The companies changing hands, returning capital to investors and giving founders their first real liquidity are not the unicorns that dominated conference stages in 2021. They are the $25M to $250M enterprise value businesses that quietly built revenue, won regulated customers and reached the point where a strategic buyer or a private equity platform can do something with them.
This is the lower mid-market, and in 2026 it has become the engine of M&A, liquidity and shareholder value realisation across European healthtech, medtech and health AI. The IPO window never reopened in any meaningful way for sub-scale healthcare technology companies. Mega-rounds dried up. What filled the gap was a steady, pragmatic flow of acquisitions, carve-outs, roll-ups and PE platform deals, concentrated in exactly the size band where most of Europe's healthtech companies actually sit.
Two things have made this possible.
The first is supply: a decade of venture investment into European digital health, medical devices and clinical software has produced a deep bench of companies with $5M to $50M of revenue, regulatory clearances, NHS or DACH or Nordic customer bases, and investors who need an exit.
The second is a change in who executes the deals. A new category of adviser, the Founder Banker, has emerged to serve this band. These are practitioners who have built, scaled and sold healthtech companies themselves, and who now run M&A mandates with the operational fluency that the bulge bracket cannot offer and the generalist boutique does not have.
London based Nelson Advisors has become the most visible example of this model, positioning itself as the gateway between North American capital and European targets, and between European founders and North American acquirers.
This article sets out why the lower mid-market has become the centre of gravity for European healthtech M&A, why liquidity now runs through acquisitions rather than public markets, why London sits at the hinge of the transatlantic corridor, and why the Founder Banker is the right instrument for the decade ahead.
What the lower mid-market actually looks like
The lower mid-market is not a vague label. In European healthtech it describes a specific kind of company: $5M to $50M of revenue, $1M to $10M of EBITDA or a credible path to it, 20 to 250 employees, and a product that has cleared the regulatory and procurement hurdles that kill most early-stage health businesses. These companies have CE marks or UKCA certification, MDR or IVDR files that are current, NHS framework listings, DiGA approvals in Germany or reimbursement codes in France. They have survived the hard part.
The band has grown for three reasons.
First, the 2019 to 2022 funding cycle planted an unusually large cohort of companies, and the survivors from that cohort are now reaching the scale where M&A makes sense.
Second, deal sizes have moved up. Nelson Advisors' own analysis puts the average European healthtech transaction at roughly $13.6M in early 2022, rising to an estimated $46.6M by early 2026, a more than threefold increase. The centre of the distribution has shifted squarely into the $25M to $250M corridor.
Third, capital at the very top has concentrated. Large sponsors have chased a shrinking number of billion-dollar platforms, which has left the band below $250M comparatively uncrowded and, for the right buyer, attractively priced.
The sector mix within the band is broad, and the valuation dispersion is wide. A rough 2026 picture, drawing on the same Nelson Advisors analysis:
Sub-sector | EV / Revenue (2026 outlook) | What drives the premium |
AI-native clinical and diagnostic software | 6.0x to 8.0x+ | Proprietary models, interpretability, EU AI Act readiness |
Data and interoperability infrastructure | 5.5x to 7.0x | EHDS readiness, native EHR integration |
Value-based care platforms | 5.5x to 7.0x | Demonstrated payer ROI, reimbursement lock-in |
General healthtech SaaS | 4.0x to 6.0x | Rule of 40, net retention above 105% |
MDR-ready medtech hardware | 3.5x to 5.0x | Completed Class IIb/III certification, consumables |
Revenue cycle and back-office health IT | 3.5x to 5.0x | Automation, roll-up potential |
Unprofitable early-stage digital health | 3.0x to 4.0x | Distressed; needs recapitalisation |
The spread between the top and bottom of that table is the whole story of lower mid-market healthtech M&A. The same $20M-revenue company can be worth $60M or $160M depending on whether its product is a clinical AI with regulatory clearance or a consumer wellness app with high churn. The adviser who understands why, and can evidence it to a buyer, changes the outcome.
Three structural features define this band from an execution standpoint. Processes are usually bilateral or limited rather than broad auctions. Buyers are a mix of PE-backed platforms looking for add-ons, mid-cap strategics filling product gaps, and North American acquirers buying a European beachhead. And founders typically remain shareholders through the deal, rolling 20% to 40% of their equity into the acquiring platform, which makes the quality of the buyer and the structure of the deal as important as the headline price.
Liquidity now comes from M&A, not the public markets
For a European healthtech company valued below $250M, the IPO is no longer a realistic exit. London's junior markets have struggled to attract and sustain healthcare technology listings. Euronext and the Nordic exchanges have handled a handful of medtech floats, but liquidity on the secondary market for sub-$500M healthcare names is thin, research coverage is sparse, and the post-listing performance of many 2020 and 2021 vintage listings scared off the next cohort. A US listing is only an option for companies with $100M-plus of revenue and a story that Nasdaq investors already understand.
That leaves four routes to liquidity for shareholders in this band, and all four are variations on M&A:
Sale to a strategic acquirer. The cleanest route. A larger healthtech, medtech or health IT company buys the business for its product, customer base, regulatory asset or team. Price is driven by strategic fit rather than financial metrics alone.
Sale to a private equity platform. Increasingly common. A PE-backed consolidator acquires the company as an add-on, and the founders roll part of their equity. The founders get partial liquidity now and a second exit later when the platform sells.
Primary platform investment. A PE sponsor takes a majority position in the company as a new platform, usually with founders retaining a meaningful minority and the sponsor funding buy-and-build.
Secondary or structured liquidity. Growth investors or secondary funds buy out early-stage investors and some founder equity, without a change of control.
Each of these is an M&A transaction in substance. Each requires a buyer to be found, a process to be run, a valuation to be evidenced and defended, and a structure to be negotiated. The investor base that funded European healthtech between 2015 and 2022 is now a decade into fund lives and needs distributions. The founders who built those companies are often eight to twelve years in and need to realise some personal value. The supply of sellers is structural, not cyclical.
The demand side has also strengthened. Nelson Advisors' mid-year analysis noted that by mid-2025 European healthcare deal value had risen sharply even as deal counts fell, with buyers paying up for fewer, better assets. The first half of 2026 showed the same pattern in medtech: value up strongly, volume roughly flat, average deal size rising. Buyers are being selective, which rewards companies that can present clean regulatory files, defensible unit economics and a credible growth story.
The practical consequence is that shareholder value in European healthtech is realised through
transactions in the $25M to $250M band, executed by advisers who know how to run those transactions. Realising value is no longer about waiting for a market window. It is about preparation, positioning, buyer access and negotiation. That is an execution problem, and execution problems get solved by people who have done it before.
London as the hinge of the transatlantic corridor
The single most important buyer group for European lower mid-market healthtech is North American. US and Canadian strategics and sponsors have the cheque sizes, the appetite and, increasingly, the strategic need. The US market has consolidated hard in health IT, ambient AI, revenue cycle and digital MSK, and acquirers are now looking outward for differentiated clinical products, regulatory assets and new geographies. European companies that have already passed MDR, built interoperability with national health systems or demonstrated outcomes in a single-payer environment are exactly what those buyers cannot easily build at home.
The traffic runs both ways. North American healthtech and medtech companies that want European revenue need a route into a fragmented continent of 27-plus healthcare systems, each with its own reimbursement logic. Buying a $30M to $80M EV business with existing contracts and local regulatory standing is faster, cheaper and less risky than building a European go-to-market from scratch. Market entry by acquisition has become a standard play.
London sits at the hinge of this corridor for reasons that go beyond time zones. It shares a language and a legal tradition with the US and Canada. English-law share purchase agreements, warranty and indemnity insurance markets and a deep bench of healthcare-literate lawyers and accountants make it the natural venue for a cross-border deal. The NHS, for all its procurement complexity, is the largest single-payer health system in the Western world and a credible proving ground that American buyers recognise. The UK also hosts the densest concentration of healthtech, medtech and health AI companies in Europe, alongside Berlin, Paris, Stockholm and Amsterdam, and it is where most European healthcare venture and growth investors are based or have an office.
What London did not have, until recently, was an advisory layer built for this corridor at the lower mid-market scale. The large banks have transatlantic healthcare coverage but their economics do not work below $250M EV. The US boutiques know American buyers but not European founders, regulators or payers. The European generalist boutiques know local corporate finance but struggle to explain a DiGA approval or an EU AI Act conformity assessment to a Boston-based acquirer, and they do not have relationships with the strategic corporate development teams in Minneapolis, Toronto or San Francisco.
That gap is what the Founder Banker model fills. An adviser based in London with lived experience of building healthtech companies, exits to North American and FTSE-listed acquirers, and standing relationships on both sides of the Atlantic can originate a mandate in Munich, position it for a buyer in Chicago and close under English law in Mayfair. Nelson Advisors has made this corridor its explicit focus, with a stated coverage spanning the UK, Western Europe, North America and the Commonwealth, and an events calendar that runs from Rewired and NHS ConfedExpo through HLTH Europe, HIMSS in New York, HLTH USA and the Venture Capital World Summit in Toronto. The firm is physically in London but its market is the corridor.
The rise of the Founder Banker
The Founder Banker is a new category of M&A adviser.
The defining characteristic is not a banking background but an operating one: these are people who have founded, scaled, funded and sold healthtech companies themselves, and who then moved into advisory with that experience intact. They run sell-side and buy-side mandates, structure partnerships and advise boards, but they do so from the perspective of someone who has sat on the other side of the table as a shareholder with their own equity at stake.
Nelson Advisors is the clearest expression of this model in Europe.
Established in 2023 and based in Marylebone, London, the firm describes its DNA as healthtech entrepreneurs advising healthtech entrepreneurs. Its founding partners have built, scaled and exited four healthtech businesses since 2012, spanning patient engagement, medical device cybersecurity, metabolic health and consumer health, with exits to North American, European and FTSE-listed acquirers. They combine that with institutional banking training, business school credentials and board roles across digital MSK, workforce management, wearables, healthcare AI and direct-to-consumer health. The firm focuses exclusively on healthtech, medtech, digital health, health IT and health AI in the $25M to $250M EV band.
Why does this matter in practice?
Because lower mid-market healthtech deals fail or underperform for reasons that are operational, not financial. A buyer's diligence team will ask whether the clinical evaluation report is current, whether the software architecture can pass a security review, whether the NHS contracts are actually renewable, whether the AI model will survive an EU AI Act conformity assessment, whether the sales pipeline is real. A banker who has never run a healthtech company cannot anticipate those questions, prepare the company for them or argue credibly when a buyer uses them to chip the price. A Founder Banker has lived every one of them.
The bulge bracket has effectively exited this band. Fee economics mean a global bank cannot staff a $60M sale with the senior attention it needs, and the junior team it does assign will not understand the asset. Generalist regional boutiques have the opposite problem: senior attention but shallow sector knowledge, which shows up as mispriced assets, poorly targeted buyer lists and processes that stall in diligence. Nelson Advisors has written about this as the advisory gap, and the argument is sound. The lower mid-market has been underbanked for years, and that has left value on the table for sellers and created mis-pricing that sophisticated sponsors have exploited through bilateral outreach to founders who had no adviser at all.
The Founder Banker closes that gap from the seller's side. By bringing operational expertise and sector depth to a size band that the large banks ignore and the generalists cannot serve, the model gives founders and their investors a credible process, a competitive buyer set and a defensible valuation. The firm's Build, Buy, Partner, Sell framework reflects this: the conversation often starts well before a sale, with a founder trying to decide whether to raise, acquire, partner or exit, and the adviser's job is to help the board choose the right route and then execute it.
Three edges: operational expertise, market access, domain depth
The Founder Banker model rests on three advantages that reinforce each other. Each one is hard to replicate, and together they explain why this model is winning mandates in the lower mid-market.
Operational expertise. Having built and sold healthtech companies, the Founder Banker understands the inside of the business being sold. That translates into better preparation. The data room is built around what a healthcare buyer will actually ask for: regulatory files, clinical evidence, information governance, contract renewal schedules, churn by customer cohort, integration dependencies. The management presentation anticipates the questions a corporate development team at a US medtech will raise about MDR, QMSR alignment and US market entry. Negotiation improves too. A founder-turned-banker knows which warranty exposures matter, which earn-out metrics are achievable and which working capital adjustments are reasonable, because they have signed those documents on their own deals. In a band where headline price and net proceeds can diverge by 20% or more depending on structure, that knowledge is worth real money.
Unrivalled market access. Access is the quiet differentiator. Founders talk to founders. A Founder Banker who has been through an exit is part of the founder community in a way a career banker cannot be, and that produces a steady flow of early conversations, often years before a company is ready to sell. On the buy side, the same experience earns credibility with corporate development teams, PE deal partners and growth investors who have seen the adviser operate as a principal. Nelson Advisors has invested in this access deliberately: a weekly European healthtech M&A newsletter with more than 5,000 subscribers, a publishing platform at healthcare.digital, chairing M&A panels at the HealthInvestor Healthcare Summit and HealthTech X, judging the Rewired PitchFest, and guest lecturing at UCL's Global Business School for Health, Oxford, Cambridge Judge and IESE. That footprint keeps the firm in front of the founders, investors and acquirers that make up the lower mid-market, on both sides of the Atlantic.
Deep sector domain expertise. Healthtech is not software with a stethoscope. The regulatory layer alone is a specialist discipline: MDR and IVDR, UKCA, the EU AI Act's requirements for high-risk clinical AI, the European Health Data Space, the FDA's harmonised QMSR, DiGA, PECAN, NHS DTAC and the Digital Clinical Safety standards. Reimbursement differs by country. Procurement cycles are long and political. A Founder Banker who has navigated those systems can value a company correctly, identify the buyers for whom a particular regulatory asset is strategic, and explain to a North American acquirer why a Class IIb certification or a DiGA listing justifies a premium. Nelson Advisors publishes detailed sector analysis every week on valuation multiples, deal structures, distressed M&A, ambient AI consolidation and sub-sector hotspots, which is both a service to the market and a demonstration of the domain depth that underpins its mandates.
The three edges compound. Operational expertise makes the adviser credible with founders, which drives access. Access generates proprietary deal flow and buyer relationships. Domain depth converts those relationships into transactions that price correctly and close. Remove any one of the three and the model weakens: a banker with access but no operating experience cannot prepare the company; an operator with no network cannot find the buyer; a networker without sector depth cannot defend the price.
What this means for founders, investors and buyers
For founders, the implication is that an exit is a project to be prepared, not an event to be waited for. The companies that achieve the top of the valuation range in their sub-sector share a set of characteristics that can be built deliberately over 12 to 24 months: a current and complete regulatory file, clinical or economic evidence that a buyer's medical director will accept, net revenue retention above 105%, a profit-weighted Rule of 40 profile, a clean cap table, and a management team that can survive the founder stepping back.
A Founder Banker engaged early will tell a founder which of those gaps matters most to the likely buyer set and how to close it. Founders should also expect to roll equity. Partial liquidity now plus a second bite on the platform exit is the dominant structure in this band, and choosing the right platform matters as much as the first-round price.
For venture and growth investors, the lower mid-market is where distributions will come from for the rest of this decade. Funds raised between 2015 and 2021 are carrying portfolios of healthtech companies that will not IPO and will not raise another large round. The realistic path to DPI is a well-run sale in the $25M to $250M band. That argues for engaging specialist advisers across the portfolio early, pushing portfolio companies toward exit-ready metrics, and being realistic about the valuation step-down from the last primary round. It also argues against bilateral approaches from sponsors who have identified an underbanked asset. Those approaches are sometimes attractive, but a company that enters a bilateral negotiation without a specialist adviser is almost certainly leaving money on the table.
For private equity sponsors and strategic buyers, the thesis is well established: founder-led healthtech businesses with $1M to $10M of EBITDA trade at a structural discount to the multiples paid once a platform crosses $10M of EBITDA, and buy-and-build across Europe's fragmented markets captures that step-up.
The Founder Banker is relevant on the buy side too. Sourcing proprietary targets across DACH, the Nordics, Benelux, France and the UK requires relationships with founders who do not answer cold emails from a deal team. Diligencing a clinical AI company or a Class III device business requires sector judgement that a generalist adviser cannot provide. And integrating an acquired European healthtech company into a North American platform benefits from advisers who have run that integration themselves.
For all three groups, the common thread is that value is realised through the quality of execution in the $25M to $250M band. The deal size is where the market has moved. The adviser model is what determines whether a given deal lands at the top or the bottom of the range, and whether it closes at all. In a market that is paying up for quality and discounting everything else, that difference has never been larger.
The next decade of European healthtech M&A
The future of healthtech M&A in Europe will be written in the $25M to $250M enterprise value band, and it will be executed by Founder Bankers. That is not a prediction about fashion. It follows from the structure of the market. The supply of exit-ready companies is deep and growing. The public markets are closed to companies of that size. North American buyers need European assets and European companies need North American capital, and London is the natural venue for that exchange.
The bulge bracket cannot serve the band economically and the generalist boutiques cannot serve it competently. The adviser that combines operating experience, founder and investor access, and sector depth is the one that will win the mandates and deliver the outcomes.
Three things will shape how this plays out. Regulation will keep acting as a filter and a catalyst: the EU AI Act, MDR and IVDR deadlines, EHDS and the FDA's QMSR harmonisation all reward companies that are ready and punish those that are not, creating both premium assets and distressed opportunities.
Consolidation will accelerate in the sub-sectors where fragmentation is highest, including ambient clinical AI, practice management, revenue cycle, interoperability middleware and connected devices. And the transatlantic corridor will widen as US strategics, having consolidated their home market, look to Europe for the next phase of growth.
For the founders who built this generation of European healthtech companies, the opportunity is to realise the value they created. For the investors who backed them, it is to return capital to limited partners who have waited a long time. For the buyers, it is to acquire differentiated clinical technology at prices that still reflect a structural discount. The Founder Banker is the mechanism that connects those three interests, and Nelson Advisors has shown what the model looks like when it is built in London with the corridor in mind.
The mid-market has grown up. The advisory model has caught up with it. The next decade belongs to both.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments